The Prognostic Value of the New Combined Hemo-Eosinophil Inflammation Index (HEI Index): A Multicenter Analysis of Anal Cancer Patients Treated with Concurrent Chemo-Radiation
Anal squamous cell carcinoma (SCC) is a rare tumor, and bio-humoral predictors of response to chemo-radiation (CT-RT) are lacking. We developed a prognostic score system based on laboratory inflammation parameters. We investigated the correlation between baseline clinical and laboratory variables an...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-02-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/4/671 |
| _version_ | 1797413094510559232 |
|---|---|
| author | Margherita Rimini Pierfrancesco Franco Berardino De Bari Maria Giulia Zampino Stefano Vagge Giovanni Luca Frassinetti Francesca Arcadipane Almalina Bacigalupo Martina Valgiusti Deborah Aloi Lorenzo Gervaso Renzo Corvò Giulia Bartolini Marianna Alessandra Gerardi Stefano Cascinu Andrea Casadei-Gardini |
| author_facet | Margherita Rimini Pierfrancesco Franco Berardino De Bari Maria Giulia Zampino Stefano Vagge Giovanni Luca Frassinetti Francesca Arcadipane Almalina Bacigalupo Martina Valgiusti Deborah Aloi Lorenzo Gervaso Renzo Corvò Giulia Bartolini Marianna Alessandra Gerardi Stefano Cascinu Andrea Casadei-Gardini |
| author_sort | Margherita Rimini |
| collection | DOAJ |
| description | Anal squamous cell carcinoma (SCC) is a rare tumor, and bio-humoral predictors of response to chemo-radiation (CT-RT) are lacking. We developed a prognostic score system based on laboratory inflammation parameters. We investigated the correlation between baseline clinical and laboratory variables and disease-free (DFS) and overall (OS) survival in anal SCC patients treated with CT-RT in five institutions. The bio-humoral parameters of significance were included in a new scoring system, which was tested with other significant variables in a Cox’s proportional hazard model. A total of 308 patients was included. We devised a prognostic model by combining baseline hemoglobin level, SII, and eosinophil count: the Hemo-Eosinophils Inflammation (HEI) Index. We stratified patients according to the HEI index into low- and high-risk groups. Median DFS for low-risk patients was not reached, and it was found to be 79.5 months for high-risk cases (Hazard Ratio 3.22; 95% CI: 2.04–5.10; <i>p</i> < 0.0001). Following adjustment for clinical covariates found significant at univariate analysis, multivariate analysis confirmed the HEI index as an independent prognostic factor for DFS and OS. The HEI index was shown to be a prognostic parameter for DFS and OS in anal cancer patients treated with CT-RT. An external validation of the HEI index is mandatory for its use in clinical practice. |
| first_indexed | 2024-03-09T05:12:35Z |
| format | Article |
| id | doaj.art-0a82faaa05d144dfa022b800224a7ea2 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T05:12:35Z |
| publishDate | 2021-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-0a82faaa05d144dfa022b800224a7ea22023-12-03T12:48:05ZengMDPI AGCancers2072-66942021-02-0113467110.3390/cancers13040671The Prognostic Value of the New Combined Hemo-Eosinophil Inflammation Index (HEI Index): A Multicenter Analysis of Anal Cancer Patients Treated with Concurrent Chemo-RadiationMargherita Rimini0Pierfrancesco Franco1Berardino De Bari2Maria Giulia Zampino3Stefano Vagge4Giovanni Luca Frassinetti5Francesca Arcadipane6Almalina Bacigalupo7Martina Valgiusti8Deborah Aloi9Lorenzo Gervaso10Renzo Corvò11Giulia Bartolini12Marianna Alessandra Gerardi13Stefano Cascinu14Andrea Casadei-Gardini15Department of Oncology and Hematology, Division of Oncology, University Hospital Modena, 41000 Modena, ItalyDepartment of Oncology, Radiation Oncology, University of Turin, 10126 Turin, ItalyDepartment of Radiation Oncology, University Hospital of Besançon, 25000 Besançon, FranceDivision of Gastrointestinal Oncology and Neuroendocrine Tumors, European Institute of Oncology, IRCCS, 20019 Milan, ItalyDepartment of Radiation Oncology, IRCCS Ospedale Policlinico San Martino, 16121 Genova, ItalyDepartment of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori ‘Dino Amadori’–IRST, 47014 Meldola, ItalyDepartment of Oncology, Radiation Oncology, University of Turin, 10126 Turin, ItalyDepartment of Radiation Oncology, IRCCS Ospedale Policlinico San Martino, 16121 Genova, ItalyDepartment of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori ‘Dino Amadori’–IRST, 47014 Meldola, ItalyDepartment of Radiation Oncology, University Hospital of Besançon, 25000 Besançon, FranceDivision of Gastrointestinal Oncology and Neuroendocrine Tumors, European Institute of Oncology, IRCCS, 20019 Milan, ItalyDepartment of Radiation Oncology, IRCCS Ospedale Policlinico San Martino and Health Science Department (DISSAL), University of Genova, 16121 Genova, ItalyDepartment of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori ‘Dino Amadori’–IRST, 47014 Meldola, ItalyDivision of Radiotherapy, European Institute of Oncology, IRCCS, 20019 Milan, ItalyDepartment of Oncology, IRCCS San Raffaele Scientific Institute Hospital, 20019 Milan, ItalyDepartment of Oncology, IRCCS San Raffaele Scientific Institute Hospital, 20019 Milan, ItalyAnal squamous cell carcinoma (SCC) is a rare tumor, and bio-humoral predictors of response to chemo-radiation (CT-RT) are lacking. We developed a prognostic score system based on laboratory inflammation parameters. We investigated the correlation between baseline clinical and laboratory variables and disease-free (DFS) and overall (OS) survival in anal SCC patients treated with CT-RT in five institutions. The bio-humoral parameters of significance were included in a new scoring system, which was tested with other significant variables in a Cox’s proportional hazard model. A total of 308 patients was included. We devised a prognostic model by combining baseline hemoglobin level, SII, and eosinophil count: the Hemo-Eosinophils Inflammation (HEI) Index. We stratified patients according to the HEI index into low- and high-risk groups. Median DFS for low-risk patients was not reached, and it was found to be 79.5 months for high-risk cases (Hazard Ratio 3.22; 95% CI: 2.04–5.10; <i>p</i> < 0.0001). Following adjustment for clinical covariates found significant at univariate analysis, multivariate analysis confirmed the HEI index as an independent prognostic factor for DFS and OS. The HEI index was shown to be a prognostic parameter for DFS and OS in anal cancer patients treated with CT-RT. An external validation of the HEI index is mandatory for its use in clinical practice.https://www.mdpi.com/2072-6694/13/4/671squamous cell anal cancerprognostic factorsinflammationprognostic index |
| spellingShingle | Margherita Rimini Pierfrancesco Franco Berardino De Bari Maria Giulia Zampino Stefano Vagge Giovanni Luca Frassinetti Francesca Arcadipane Almalina Bacigalupo Martina Valgiusti Deborah Aloi Lorenzo Gervaso Renzo Corvò Giulia Bartolini Marianna Alessandra Gerardi Stefano Cascinu Andrea Casadei-Gardini The Prognostic Value of the New Combined Hemo-Eosinophil Inflammation Index (HEI Index): A Multicenter Analysis of Anal Cancer Patients Treated with Concurrent Chemo-Radiation Cancers squamous cell anal cancer prognostic factors inflammation prognostic index |
| title | The Prognostic Value of the New Combined Hemo-Eosinophil Inflammation Index (HEI Index): A Multicenter Analysis of Anal Cancer Patients Treated with Concurrent Chemo-Radiation |
| title_full | The Prognostic Value of the New Combined Hemo-Eosinophil Inflammation Index (HEI Index): A Multicenter Analysis of Anal Cancer Patients Treated with Concurrent Chemo-Radiation |
| title_fullStr | The Prognostic Value of the New Combined Hemo-Eosinophil Inflammation Index (HEI Index): A Multicenter Analysis of Anal Cancer Patients Treated with Concurrent Chemo-Radiation |
| title_full_unstemmed | The Prognostic Value of the New Combined Hemo-Eosinophil Inflammation Index (HEI Index): A Multicenter Analysis of Anal Cancer Patients Treated with Concurrent Chemo-Radiation |
| title_short | The Prognostic Value of the New Combined Hemo-Eosinophil Inflammation Index (HEI Index): A Multicenter Analysis of Anal Cancer Patients Treated with Concurrent Chemo-Radiation |
| title_sort | prognostic value of the new combined hemo eosinophil inflammation index hei index a multicenter analysis of anal cancer patients treated with concurrent chemo radiation |
| topic | squamous cell anal cancer prognostic factors inflammation prognostic index |
| url | https://www.mdpi.com/2072-6694/13/4/671 |
| work_keys_str_mv | AT margheritarimini theprognosticvalueofthenewcombinedhemoeosinophilinflammationindexheiindexamulticenteranalysisofanalcancerpatientstreatedwithconcurrentchemoradiation AT pierfrancescofranco theprognosticvalueofthenewcombinedhemoeosinophilinflammationindexheiindexamulticenteranalysisofanalcancerpatientstreatedwithconcurrentchemoradiation AT berardinodebari theprognosticvalueofthenewcombinedhemoeosinophilinflammationindexheiindexamulticenteranalysisofanalcancerpatientstreatedwithconcurrentchemoradiation AT mariagiuliazampino theprognosticvalueofthenewcombinedhemoeosinophilinflammationindexheiindexamulticenteranalysisofanalcancerpatientstreatedwithconcurrentchemoradiation AT stefanovagge theprognosticvalueofthenewcombinedhemoeosinophilinflammationindexheiindexamulticenteranalysisofanalcancerpatientstreatedwithconcurrentchemoradiation AT giovannilucafrassinetti theprognosticvalueofthenewcombinedhemoeosinophilinflammationindexheiindexamulticenteranalysisofanalcancerpatientstreatedwithconcurrentchemoradiation AT francescaarcadipane theprognosticvalueofthenewcombinedhemoeosinophilinflammationindexheiindexamulticenteranalysisofanalcancerpatientstreatedwithconcurrentchemoradiation AT almalinabacigalupo theprognosticvalueofthenewcombinedhemoeosinophilinflammationindexheiindexamulticenteranalysisofanalcancerpatientstreatedwithconcurrentchemoradiation AT martinavalgiusti theprognosticvalueofthenewcombinedhemoeosinophilinflammationindexheiindexamulticenteranalysisofanalcancerpatientstreatedwithconcurrentchemoradiation AT deborahaloi theprognosticvalueofthenewcombinedhemoeosinophilinflammationindexheiindexamulticenteranalysisofanalcancerpatientstreatedwithconcurrentchemoradiation AT lorenzogervaso theprognosticvalueofthenewcombinedhemoeosinophilinflammationindexheiindexamulticenteranalysisofanalcancerpatientstreatedwithconcurrentchemoradiation AT renzocorvo theprognosticvalueofthenewcombinedhemoeosinophilinflammationindexheiindexamulticenteranalysisofanalcancerpatientstreatedwithconcurrentchemoradiation AT giuliabartolini theprognosticvalueofthenewcombinedhemoeosinophilinflammationindexheiindexamulticenteranalysisofanalcancerpatientstreatedwithconcurrentchemoradiation AT mariannaalessandragerardi theprognosticvalueofthenewcombinedhemoeosinophilinflammationindexheiindexamulticenteranalysisofanalcancerpatientstreatedwithconcurrentchemoradiation AT stefanocascinu theprognosticvalueofthenewcombinedhemoeosinophilinflammationindexheiindexamulticenteranalysisofanalcancerpatientstreatedwithconcurrentchemoradiation AT andreacasadeigardini theprognosticvalueofthenewcombinedhemoeosinophilinflammationindexheiindexamulticenteranalysisofanalcancerpatientstreatedwithconcurrentchemoradiation AT margheritarimini prognosticvalueofthenewcombinedhemoeosinophilinflammationindexheiindexamulticenteranalysisofanalcancerpatientstreatedwithconcurrentchemoradiation AT pierfrancescofranco prognosticvalueofthenewcombinedhemoeosinophilinflammationindexheiindexamulticenteranalysisofanalcancerpatientstreatedwithconcurrentchemoradiation AT berardinodebari prognosticvalueofthenewcombinedhemoeosinophilinflammationindexheiindexamulticenteranalysisofanalcancerpatientstreatedwithconcurrentchemoradiation AT mariagiuliazampino prognosticvalueofthenewcombinedhemoeosinophilinflammationindexheiindexamulticenteranalysisofanalcancerpatientstreatedwithconcurrentchemoradiation AT stefanovagge prognosticvalueofthenewcombinedhemoeosinophilinflammationindexheiindexamulticenteranalysisofanalcancerpatientstreatedwithconcurrentchemoradiation AT giovannilucafrassinetti prognosticvalueofthenewcombinedhemoeosinophilinflammationindexheiindexamulticenteranalysisofanalcancerpatientstreatedwithconcurrentchemoradiation AT francescaarcadipane prognosticvalueofthenewcombinedhemoeosinophilinflammationindexheiindexamulticenteranalysisofanalcancerpatientstreatedwithconcurrentchemoradiation AT almalinabacigalupo prognosticvalueofthenewcombinedhemoeosinophilinflammationindexheiindexamulticenteranalysisofanalcancerpatientstreatedwithconcurrentchemoradiation AT martinavalgiusti prognosticvalueofthenewcombinedhemoeosinophilinflammationindexheiindexamulticenteranalysisofanalcancerpatientstreatedwithconcurrentchemoradiation AT deborahaloi prognosticvalueofthenewcombinedhemoeosinophilinflammationindexheiindexamulticenteranalysisofanalcancerpatientstreatedwithconcurrentchemoradiation AT lorenzogervaso prognosticvalueofthenewcombinedhemoeosinophilinflammationindexheiindexamulticenteranalysisofanalcancerpatientstreatedwithconcurrentchemoradiation AT renzocorvo prognosticvalueofthenewcombinedhemoeosinophilinflammationindexheiindexamulticenteranalysisofanalcancerpatientstreatedwithconcurrentchemoradiation AT giuliabartolini prognosticvalueofthenewcombinedhemoeosinophilinflammationindexheiindexamulticenteranalysisofanalcancerpatientstreatedwithconcurrentchemoradiation AT mariannaalessandragerardi prognosticvalueofthenewcombinedhemoeosinophilinflammationindexheiindexamulticenteranalysisofanalcancerpatientstreatedwithconcurrentchemoradiation AT stefanocascinu prognosticvalueofthenewcombinedhemoeosinophilinflammationindexheiindexamulticenteranalysisofanalcancerpatientstreatedwithconcurrentchemoradiation AT andreacasadeigardini prognosticvalueofthenewcombinedhemoeosinophilinflammationindexheiindexamulticenteranalysisofanalcancerpatientstreatedwithconcurrentchemoradiation |